Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Largest Number of Consultations Requested by US Ventures: JETRO
May 16, 2005
- Towa Seeking Partnership to Build Marketing Route to Major Hospitals
May 16, 2005
- Wave of Buy-outs Unlikely in Japan: Mr Mikel of IMS Health
May 16, 2005
- Terumo Aiming for Sales of \300 Bil. in FY2007
May 16, 2005
- NEW PRODUCTS
May 16, 2005
- NBI Reaffirms Sales Target of \100 Bil. for FY2005
May 16, 2005
- SUEVEY
May 16, 2005
- Shionogi to Focus on Pain and Metabolic Syndrome in Addition to Infections
May 16, 2005
- PMDA Announces Provisional Measures to Improve Clinical Trial Consultation
May 16, 2005
- Mitsubishi Chemical, Mitsubishi Pharma to Come under New Holding Company
May 16, 2005
- JASMO Announces FY2005 Plans of Action
May 16, 2005
- MEDICAL DEVICE NEWS IN BRIEF
May 16, 2005
- 5th Bio Business Competition Japan
May 16, 2005
- R&D NEWS IN BRIEF
May 16, 2005
- WEBSITE NEWS
May 16, 2005
- REGULATORY NEWS IN BRIEF
May 16, 2005
- AstraZeneca to Recommend 5 mg Starting Dose of Crestor to Asians: EU Label
May 16, 2005
- Business Results
May 16, 2005
- NEW PRODUCTS
May 16, 2005
- Daiichi: Ethical Drug Sales Up 2.4% to \311,844 Mil.
May 16, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…